Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cordlife GroupCLIFF 42 3-1 Month Momentum % is 113.75% as of Jul. 29, 2026. GuruFocus rates CLIFF with a GF Score™ of 42/100 and a GF Value™ of $0.08 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 215 Medical Diagnostics & Research companies, Cordlife Group ranks worse than 84.19% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-29), Cordlife Group's 3-1 Month Momentum % is 113.75%.
The industry rank for Cordlife Group's 3-1 Month Momentum % or its related term are showing as below:
CLIFF's 3-1 Month Momentum % is ranked worse than 84.19% of 215
companies
in the Medical Diagnostics & Research industry
Industry Median: -4.1
vs CLIFF: 113.75
Cordlife Group (OTCPK:CLIFF) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Cordlife Group 3-1 Month Momentum % Related Terms
CLIFF vs TMO, DHR, IDXX: 3-1 Month Momentum % Comparison
For the Diagnostics & Research subindustry, Cordlife Group's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cordlife Group 3-1 Month Momentum % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Cordlife Group's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Cordlife Group's 3-1 Month Momentum % falls into.
Cordlife Group (OTCPK:CLIFF) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cordlife Group (CLIFF) has a 3-1 Month Momentum % of 113.75% as of Jul. 29, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Cordlife Group and its competitors. According to the industry distribution chart, Cordlife Group ranks #181 out of 215 companies in the Medical Diagnostics & Research industry, placing it in the top 84.2%.
Is Cordlife Group's 3-1 Month Momentum % too high?
Cordlife Group's current 3-1 Month Momentum % is 113.75%. Based on the distribution chart, Cordlife Group ranks #181 out of 215 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Cordlife Group has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cordlife Group's 3-1 Month Momentum % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Cordlife Group ranks #181 out of 215 companies for 3-1 Month Momentum %. This places Cordlife Group in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Medical Diagnostics & Research company?
A good 3-1 Month Momentum % depends on the Medical Diagnostics & Research industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Cordlife Group and its competitors. Cordlife Group's current 3-1 Month Momentum % is 113.75%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cordlife Group stock overvalued right now?
Based on GuruFocus' analysis, Cordlife Group (CLIFF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.08, compared to a current price of $0.15 — trading 88.1% above its estimated fair value. The current 3-1 Month Momentum % is 113.75%. Cordlife Group's overall GF Score™ is 42/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Cordlife Group (CLIFF), the current 3-1 Month Momentum % is 113.75% as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cordlife Group (CLIFF) Overvalued in 2026?
Based on GuruFocus' analysis, Cordlife Group stock appears to be overvalued.
The current stock price of $0.15 is trading 88.1% above its estimated GF Value™ of $0.08.
GuruFocus considers Cordlife Group to be Significantly Overvalued.
Key valuation signals for CLIFF:
3-1 Month Momentum %: 113.75%
GF Value™: $0.08 vs. price of $0.15 (88.1% above fair value)
No single metric tells the full story. See the CLIFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cordlife Group Ltd is a consumer healthcare company dedicated to safeguarding the well-being of mother and child. Along with its subsidiaries, the company is engaged in the provision of diagnostics and cord blood banking services, which involve the processing and storage of cord blood stem cells. The group has two reportable segments as follows: the Banking segment, which derives maximum revenue, comprises the collection, processing, and banking of biological materials; and the Diagnostics segment, which comprises diagnostics testing services. Geographically, the group generates maximum revenue from Hong Kong, and the rest from the Philippines, India, Malaysia, Singapore, and other regions.
42GF Score
Get the complete analysis for CLIFF
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLIFF has been successfully added to your 
